@article{a4814af4ed124feea4071a1cd519d843,
title = "Response to Haseeb et al.",
author = "Katz, {Philip O.} and Dunbar, {Kerry B.} and Schnoll-Sussman, {Felice H.} and Greer, {Katarina B.} and Rena Yadlapati and Spechler, {Stuart Jon}",
note = "Funding Information: Potential competing interests: P.O.K. has served as a consultant for Phathom Pharma and Medtronic, research support: Diversatek, and royalties: UpToDate. K.D.: none currently; previous research funding from Ironwood. F.H.S.-S.: consultant for Ethicon, Interpace Biosciences, and Medtronic. K.B.G.: none. R.Y.: consultant through institutional agreement: Medtronic, Ironwood, and Diversatek; research support: Ironwood; advisory board: Phathom Pharma; and stock options: RJS Mediagnostix. S.J.S. has served as a consultant for Interpace Diagnostics, Cernostics, Phathom Pharmaceuticals, Takeda, and Ironwood Pharmaceuticals and royalties: UpToDate.",
year = "2022",
month = dec,
day = "1",
doi = "10.14309/ajg.0000000000002004",
language = "English (US)",
volume = "117",
pages = "2084--2085",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "12",
}